People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for treatment-resistant depression. According to reports, the FDA approved ...
An estimated 21 million American adults suffer from clinical depression. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...